Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 2Phase 1/2 1

Status

Terminated 3Completed 2Unknown 1

Sponsor Class

INDUSTRY 5NIH 1

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Melanoma 2Carcinoma 2Peritoneal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cisplatin 1514Carboplatin 1416Cyclophosphamide 1359Gemcitabine 1235Bevacizumab 1223Paclitaxel 1210Radiotherapy 1173Docetaxel 1079pembrolizumab 1026Oxaliplatin 934Capecitabine 898Fluorouracil 832Rituximab 729Doxorubicin 683Nivolumab 679Dexamethasone 665Etoposide 660Irinotecan 622Leucovorin 574Pemetrexed 508Drug Therapy 491Cetuximab 481Trastuzumab 467Cytarabine 466Magnetic Resonance Spectroscopy 457Filgrastim 446Prednisone 432Lenalidomide 409Specimen Handling 407Temozolomide 400

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Interventional × volociximab × Clear all
NCT00278187 2013-12-19

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Unknown
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00401570 2013-01-30

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

AbbVie

Phase 2 Completed
40 enrolled
Gastrointestinal

Carcinoma, Neoplasms, Pancreatic Neoplasms

NCT00516841 2012-08-23

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

Facet Biotech

Phase 2 Terminated
16 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00100685 2012-04-27

Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC)

Abbott

Phase 2 Terminated
48 enrolled
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT00369395 2012-04-27

A Study of Volociximab in Metastatic Melanoma

Abbott

Phase 2 Terminated
19 enrolled
Dermatologic

Melanoma

NCT00099970 2008-08-05

Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy

Facet Biotech

Phase 2 Completed
40 enrolled
Dermatologic

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡